Johnson & Johnson (NYSE:JNJ) Shares Sold by Legacy Financial Advisors Inc.

Legacy Financial Advisors Inc. lowered its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 11.4% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 15,944 shares of the company's stock after selling 2,047 shares during the quarter. Legacy Financial Advisors Inc.'s holdings in Johnson & Johnson were worth $2,306,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of JNJ. IFS Advisors LLC boosted its holdings in Johnson & Johnson by 138.9% during the 4th quarter. IFS Advisors LLC now owns 172 shares of the company's stock valued at $25,000 after acquiring an additional 100 shares during the period. WealthTrak Capital Management LLC purchased a new stake in shares of Johnson & Johnson during the fourth quarter valued at $26,000. Mountain Hill Investment Partners Corp. bought a new position in shares of Johnson & Johnson in the fourth quarter worth about $29,000. Bay Harbor Wealth Management LLC purchased a new position in Johnson & Johnson in the 4th quarter worth about $32,000. Finally, Conquis Financial LLC bought a new stake in Johnson & Johnson during the 4th quarter valued at about $33,000. Hedge funds and other institutional investors own 69.55% of the company's stock.

Johnson & Johnson Price Performance

JNJ stock traded up $1.82 during trading on Monday, hitting $153.55. The stock had a trading volume of 4,211,649 shares, compared to its average volume of 7,939,132. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99. The company's 50-day moving average price is $159.40 and its two-hundred day moving average price is $155.17. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. The stock has a market capitalization of $370.03 billion, a P/E ratio of 23.09, a PEG ratio of 2.56 and a beta of 0.49.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.99 by $0.05. The firm had revenue of $22.52 billion during the quarter, compared to analysts' expectations of $22.44 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The firm's revenue for the quarter was up 5.3% on a year-over-year basis. During the same period in the previous year, the business earned $2.29 earnings per share. As a group, research analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have commented on JNJ shares. Raymond James reduced their price objective on Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a report on Monday. The Goldman Sachs Group upgraded Johnson & Johnson from a "neutral" rating to a "buy" rating and boosted their price target for the stock from $157.00 to $172.00 in a research note on Wednesday, April 9th. Leerink Partners lowered their price target on Johnson & Johnson from $182.00 to $169.00 and set an "outperform" rating for the company in a research report on Thursday, January 23rd. Argus upgraded Johnson & Johnson to a "strong-buy" rating in a research note on Friday, January 24th. Finally, Stifel Nicolaus cut their price target on shares of Johnson & Johnson from $170.00 to $155.00 and set a "hold" rating on the stock in a report on Thursday, January 23rd. Eight equities research analysts have rated the stock with a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $171.50.

Insider Buying and Selling

In other Johnson & Johnson news, VP Robert J. Decker sold 6,999 shares of the company's stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the sale, the vice president now directly owns 21,001 shares in the company, valued at $3,483,645.88. This represents a 25.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Timothy Schmid sold 403 shares of the business's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the transaction, the executive vice president now owns 15,098 shares in the company, valued at $2,357,552.70. The trade was a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.